Qiagen N.V. (ETR:QIA)
Germany · Delayed Price · Currency is EUR | Market Cap | 7.81B -14.6% |
| Revenue (ttm) | 1.84B +3.0% |
| Net Income | 358.27M +9.6% |
| EPS | 1.72 +16.3% |
| Shares Out | n/a |
| PE Ratio | 21.79 |
| Forward PE | 17.35 |
| Dividend | 2.27 (6.03%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 49,538 |
| Open | 38.05 |
| Previous Close | 37.57 |
| Day's Range | 37.60 - 38.08 |
| 52-Week Range | 27.56 - 47.60 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial numbers in USD Financial StatementsNews
Qiagen gets FDA clearance for first QIAstat-Dx Bloodstream Infection Panel
QIAGEN (QGEN) announced that the U.S. Food and Drug Administration has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Qiagen price target raised to $45 from $38 at Citi
Citi raised the firm’s price target on Qiagen (QGEN) to $45 from $38 and keeps a Neutral rating on the shares.
Qiagen price target raised to $40 from $36 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Qiagen (QGEN) to $40 from $36 and keeps a Hold rating on the shares.
Qiagen price target raised to $40 from $38 at Barclays
Barclays raised the firm’s price target on Qiagen (QGEN) to $40 from $38 and keeps an Equal Weight rating on the shares.
Qiagen price target raised to $48 from $46 at Jefferies
Jefferies raised the firm’s price target on Qiagen (QGEN) to $48 from $46 and keeps a Buy rating on the shares. The firm adjusted its model for the Q2 print…
Qiagen Earnings Call Transcript: Q2 2026
Q2 2026 results exceeded expectations with $535M in sales and $0.62 adjusted EPS, driven by strong growth in Sample Technologies, QIAcuity, and QDI. Full-year guidance is reaffirmed, with new product launches and automation expected to drive stronger H2 growth.
Qiagen Earnings release: Q2 2026
Qiagen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Qiagen Slides: Q2 2026
Qiagen has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Qiagen reports Q2 adjusted EPS 62c, consensus 60c
Reports Q2 revenue $535M, consensus $527.46M. “QIAGEN (QGEN) delivered results above our outlook for the second quarter of 2026 while maintaining a high level of profitability in a challenging operati...
Qiagen backs FY26 adjusted EPS view at least $2.43, consensus $2.44
Full-year 2026 outlook reaffirmed for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER.
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per sha...
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions support...
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026. Press release date / time: Wednes...
Qiagen price target raised to $44 from $40 at TD Cowen
TD Cowen raised the firm’s price target on Qiagen (QGEN) to $44 from $40 and keeps a Hold rating on the shares. The firm adjusted targets in the tools space…
Qiagen expands QIAstat-Dx bloodstream infection testing menu in Europe
Qiagen (QGEN) announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform in Europe....
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN ...
Qiagen downgraded to Hold from Buy at Berenberg
Berenberg analyst Harry Gillis downgraded Qiagen (QGEN) to Hold from Buy with a price target of $45.50, down from $59. The firm is concerned about the pace at which the…
Qiagen gains after report of early PE interest including EQT, Advent
Shares of Qiagen (QGEN) are trading higher after following reports that the European molecular testing company has drawn early takeover interest from firms including EQT AB (EQBBF) and Advent. KKR…
Qiagen draws early takeover interest from EQT, Advent & KKR, Bloomberg News reports
Qiagen is drawing early takeover interest from buyout firms, including EQT AB , Advent and KKR , Bloomberg News said on Thursday, citing people familiar with the matter.
Qiagen drawing takeover interest from Advent, EQT, Bloomberg reports
According to the report, some of Qiagen’s (QGEN) suitors are considering offering at least $50 per share.
Qiagen initiated with a Hold at Kepler Cheuvreux
Kepler Cheuvreux initiated coverage of Qiagen (QGEN) with a Hold rating and $38.60 price target The firm views the company as a “solid franchise,” citing its greater exposure to life…
Qiagen Transcript: AGM 2026
The AGM highlighted strong 2025 financial results, a 40% dividend increase, and board renewal. Shareholders approved all proposals, including share buybacks and auditor reappointment, while management addressed questions on capital allocation and strategic direction.
Qiagen Slides: FY 2026
Qiagen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 24, 2026.
Qiagen upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Qiagen (QGEN) to Overweight from Equal Weight with a price target of $42, up from $40. The firm says signs of a growth inflection coupled with sector…